A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

NCT01191268 · Completed

Last updated 2026-05-28

This clinical trial tested a new medication in adults with type 2 diabetes to see how it affects blood sugar levels over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 884 people

Who can join Ages 18+ · all sexes

Timeline Started 2010-11 · est. completion 2012-09

Where 101 sites · Argentina, Australia, Belgium, Brazil, Canada, Denmark, Greece, Hungary, Mexico, Poland, Puerto Rico, Russia, Spain, Sweden, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT01191268 ↗

Description as written by the study sponsor.

The purpose of this study is to assess the efficacy and safety of LY2189265 in comparison to Insulin Glargine, both in combination with Insulin Lispro (plus or minus Metformin), in participants with Type 2 Diabetes treated with 1 or 2 injections of insulin.

Treatments tested

Insulin Glargine Drug
LY2189265 also known as Dulaglutide Drug
Insulin Lispro Drug

Main thing measured	Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01191268 ↗